By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Syndax Pharmaceuticals Inc. 



Waltham  Massachusetts    U.S.A.
Phone: 781-839-7301 Fax:


SEARCH JOBS



Segment
Start Up





Company News
Syndax Pharmaceuticals Inc. Release: Entinostat Improves Treatment Outcomes When Combined With Immune Checkpoint Blockade In Preclinical Tumor Models 7/30/2014 8:25:39 AM
Cancer Biotech Syndax Pharmaceuticals Inc. Sets Terms For $60 Million IPO 6/6/2014 6:58:28 AM
Syndax Pharmaceuticals Inc. Announces Presentation Of Entinostat Data In Two Posters At The 2014 American Society of Clinical Oncology (ASCO) Annual Meeting 5/27/2014 6:24:36 AM
Massachusett's Syndax Pharmaceuticals Inc. Plots $69 Million IPO For Cancer Drug's Stretch Run 3/28/2014 7:05:36 AM
Syndax Pharmaceuticals Inc. Announces National Cancer Institute And FDA Reach Agreement On A Special Protocol Assessment (SPA) For The Phase 3 Trial Of Entinostat In Patients With Advanced ER+ Breast Cancer 2/13/2014 11:29:41 AM
Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax Pharmaceuticals Inc. As An Independent Director 2/3/2014 6:39:00 AM
Syndax Pharmaceuticals Inc. Announces Appointment Of Richard P. Shea As Independent Director And Chair Of The Audit Committee 1/23/2014 6:47:29 AM
Syndax Pharmaceuticals Inc. Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer 11/1/2013 6:45:34 AM
Syndax Pharmaceuticals Inc. Names Steven M. Fruchtman, M.D., Chief Medical Officer 10/11/2013 6:14:02 AM
Syndax Pharmaceuticals Inc.'s Entinostat Receives Breakthrough Therapy Designation From FDA for Treatment of Advanced Breast Cancer 9/11/2013 9:29:34 AM
123456
//-->